Literature DB >> 27888256

Corrigendum.

.   

Abstract

Lubrini G, Ríos Lago M, Periañez JA, et al. The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis. Mult Scler 2016; 22: 1607-1615. DOI: 10.1177/1352458516661047 .

Entities:  

Year:  2016        PMID： 27888256     DOI： 10.1177/1352458516681930

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.

Authors:  Simone Dallari; Diego Franciotta; Silvia Carluccio; Lucia Signorini; Matteo Gastaldi; Elena Colombo; Roberto Bergamaschi; Francesca Elia; Sonia Villani; Pasquale Ferrante; Serena Delbue
Journal:  J Neuroimmunol       Date:  2015-08-14       Impact factor: 3.478

Review 4.  Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.

Authors:  Olaf Stüve; Jeffrey L Bennett
Journal:  CNS Drug Rev       Date:  2007

5.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

6.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Authors:  M Krumbholz; I Meinl; T Kümpfel; R Hohlfeld; E Meinl
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

7.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

Authors:  Halvard Bonig; Annette Wundes; Kai-Hsin Chang; Sylvia Lucas; Thalia Papayannopoulou
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

Review 8.  Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Authors:  Rehana Z Hussain; Liat Hayardeny; Petra C Cravens; Felix Yarovinsky; Todd N Eagar; Benjamine Arellano; Krystin Deason; Cyd Castro-Rojas; Olaf Stüve
Journal:  J Neuroimmunol       Date:  2014-08-30       Impact factor: 3.478

9.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.